Contact
Subscribe

Categorie

Phase 2

[article_filters]
Website_maat_logo

October 7, 2025: MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving…
MaaT Pharma
October 7, 2025

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact

Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.

SOCIÉTÉ

Ressources

Contact

Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.

SOCIÉTÉ

Ressources

Contact

© 2026 MaaT Pharma. La mission de MaaT Pharma est de restaurer la fonction du microbiote afin de traiter des maladies potentiellement mortelles.

X-twitter Linkedin

CEO and co-founder

Hervé Affagard

Hervé Affagard is the CEO and co-founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Hervé co-founded the company alongside Dr. Joël Doré, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Hervé has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA

Linkedin-in Twitter
MaaT Pharma in the News